How Much Is Private Equity Paying for Veterinary Practices in 2026?

Key takeaways

• Private equity-backed buyers are paying 10 to 14 times normalized EBITDA for vet practices with $1 million or more in EBITDA in 2026, but typically only 60 to 80 percent of that headline number lands as cash at closing.
• The remainder splits among earnouts (paid only if performance targets are met), rollover or partnership equity (illiquid until a later defined event), and occasionally seller notes — each requires careful negotiation.
• The partnership or joint venture model is increasingly common in 2025-2026: the buyer takes 60 to 80 percent of the practice and the seller retains 20 to 40 percent with a defined buyout at a future date, typically year 5.
• Multiple arbitrage — buying practices at lower multiples and selling the combined platform at a higher multiple — is the economic engine that explains why PE-backed buyers pay what they pay.
• A structured competitive process with multiple bidders produces meaningfully better outcomes on every component of the deal, not just the headline number.

A vet I’d known professionally for a couple of years called me on a Wednesday afternoon last quarter. He’d just gotten off a one-hour call with the acquisition team at a private equity-backed veterinary group.

The offer they were teasing was, in his words, “the kind of number I’d have walked into the sunset with 20 years ago.”

He asked me a question I get often. How is private equity actually paying for veterinary practices, and is this number real?

The answer requires understanding something most owners aren’t ever taught: how private equity firms make money buying veterinary practices, what the headline number on an offer letter actually represents, and where the gap between the headline and the cash check comes from. None of this is mysterious once you see how the PE business model works, and once you understand the model, the deal structures stop feeling like a moving target and start feeling like math you can negotiate.

For coverage of where multiples actually land across practice profiles, see our veterinary practice EBITDA multiples guide. For the directory of which buyers are actually operating in the market, see our consolidator directory.

This article is about something different — the underlying economics of private equity in veterinary medicine and the deal structures that flow from those economics.

The PE business model in plain English

Private equity firms acquire individual veterinary practices not because they want to run veterinary medicine, but because the math of acquiring, integrating, and eventually selling a larger platform produces strong returns for their fund investors. The mechanics are worth understanding because they explain almost every aspect of how a PE-backed offer is structured.

A PE fund raises capital from limited partners — pension funds, endowments, sovereign wealth funds, and high-net-worth families. The fund’s general partner commits to investing that capital, generating returns, and returning proceeds to the LPs within a defined fund life, typically 10 to 12 years with the active investment period in the first 4 to 6 years.

The fund’s economic structure rewards the GP for outperforming a benchmark return (typically 8 percent annually), which means every individual investment has to support a return target meaningfully above that hurdle.

In veterinary medicine specifically, the PE business model has converged on a strategy called multiple arbitrage — the strategy of buying smaller practices at lower multiples, integrating them operationally into a larger platform, then selling the combined entity at a higher multiple. Octus’s 2025 private credit research note describes the mechanics directly, observing that equity in Western Veterinary Partners (a Tyree & D’Angelo Partners-backed platform) moved into a continuation vehicle at a “high-teens EBITDA multiple” at the platform level.

Individual practice acquisitions at the front end of that arbitrage trade in meaningfully lower multiples — particularly on direct, single-bidder sales where the buyer faces no competitive pressure.

The spread between those two numbers is the entire investment thesis. A PE-backed platform that acquires individual practices at, say, an average of 8 times EBITDA and eventually sells the integrated platform at 16 times EBITDA roughly doubles its money on the multiple alone, before accounting for any EBITDA growth from integration synergies.

That’s the math. Multiply that across hundreds of practices in a fully integrated platform, hold it for 5 to 7 years, and the returns to the fund are significant.

Understanding this matters because every component of a PE-backed offer reflects the firm’s incentives in this model. The PE buyer’s first priority is acquiring practices at multiples low enough to make the platform-level exit math work.

Their second priority is keeping the seller invested in the platform’s success through rollover equity. Their third is deferring cash through earnouts to manage their capital commitments.

None of these priorities are sinister. They’re rational expressions of the fund’s economic structure.

What the headline number on a PE offer actually represents

When a PE-backed acquisition team mentions a multiple on the first phone call — “we’re thinking about 12 times EBITDA on this practice” — that number is the total deal value, not the cash check at closing. The total deal value is the headline that goes into press releases (when deal terms are disclosed publicly) and the number sellers tend to anchor to.

The cash that actually wires into the seller’s bank account on closing day is typically much lower.

The four typical components of a PE-backed veterinary acquisition offer:

Cash at closing

Paid in full on the day the transaction closes. Per healthcare M&A legal commentary from Dechert LLP and Holland & Knight in 2025-2026, the typical range for cash at close in PE-backed practice acquisitions is 60 to 80 percent of total deal value, with variation based on practice size, buyer preferences, and the level of competitive bidding pressure on the deal.

Earnouts

Part of the sale price paid after closing, contingent on the practice hitting agreed performance targets. Earnout structures vary substantially.

Per the Dechert and Holland & Knight commentary cited above, typical earnouts in healthcare practice deals run 1 to 3 years (2 years is common) with performance metrics tied to revenue, gross profit, or EBITDA. Earnouts typically represent 10 to 25 percent of total deal value, with the actual realization rate (the percentage of maximum earnout that actually pays out) heavily dependent on the earnout structure and post-close operational decisions.

Rollover equity

A portion of ownership the seller retains in the post-sale entity instead of taking all cash at close. Rollover stakes are usually structured as ownership interests in the management services organization or a holding company above the clinical entity (the structure is necessary to satisfy corporate-practice-of-medicine restrictions in many states, per the Dechert commentary).

Rollover equity is illiquid until the platform owner exits, which typically occurs 3 to 7 years post-close. The amount of rollover required varies by buyer and by deal — typically 10 to 30 percent of deal value, occasionally more.

Seller notes

A relatively small portion of total deal value, paid out over several years post-close on a fixed schedule. Less common than the other three components.

A headline 12x offer on a practice doing $1 million in EBITDA — $12 million total deal value — might decompose as something like $8.4 million cash at close (70 percent), $1.8 million earnout over 3 years (15 percent), $1.5 million rollover equity (12.5 percent), and $300,000 seller note over 5 years (2.5 percent). What the seller spends on closing day: $8.4 million.

The rest is best-case future money that depends on operational performance, the platform owner’s eventual exit, and the seller’s continued ability to influence the practice’s post-close performance.

A real example from our work

Dr. Sarah, a practice owner in her mid-40s, received an initial direct offer of $15 million from a private equity-backed buyer.

Through our process, she closed at $22.5 million — $7.5 million of additional value that would have been left on the table with the direct deal. The competitive process took 10 days to acceptance, with funds in her account within 90 days of the original conversation.

The partnership model: a meaningfully different deal structure

One of the most important shifts in PE-backed veterinary deals over the past few years is the rise of the partnership or joint venture model. Sell-side advisors and industry commentary describe this structure as increasingly common in 2025-2026, particularly for premium multi-doctor practices where the selling vet has leverage.

The structure differs meaningfully from traditional rollover equity, and understanding the difference matters because the partnership model is often substantially more favorable to the seller.

Here is how it works. Instead of acquiring 100 percent of the practice and offering the seller rollover equity in the platform’s holding company, the PE-backed buyer acquires a majority stake in the practice itself — typically 60 to 80 percent — and the seller retains the remaining 20 to 40 percent as direct equity in the local practice entity.

The contract includes a put/call mechanism with a defined buyout date (often year 5) and a pre-set formula price for the retained equity. The formula is frequently tied to the entry multiple applied to then-current EBITDA — meaning if the entry deal was structured at 10 times EBITDA, the year-5 buyout might apply that same 10 times multiple to the practice’s EBITDA at that future point.

Some structures use the lower of the entry multiple or a market multiple at exit. Some include collars.

Why the model has spread, per legal commentary including MB Law Firm’s 2025 analysis “Joint Ventures, Longer Commitments, and the Rise of Earn-Outs” (which discusses the trend across healthcare and adjacent professional practice sectors including veterinary): it solves a problem on both sides of the deal. The buyer reduces post-close retention risk because the selling vet has real economic skin in the practice’s performance through the hold period.

The seller gets defined liquidity at a known formula price rather than illiquid platform equity that depends on a sponsor exit. The structural alignment is genuinely mutual.

The economic implications for sellers are worth working through carefully in the veterinary context specifically. In the traditional rollover structure, the seller receives a minority interest in the platform holding company, which is illiquid until the PE sponsor sells the entire platform — typically 4 to 7 years post-close, sometimes longer in slower exit environments.

The platform exit timing is uncertain. The platform exit multiple is unknown at the time of the original transaction.

Dilution from subsequent acquisitions and management equity pools can reduce the seller’s percentage. The vet seller’s return depends on the entire veterinary platform’s performance, not just their own practice.

Per Linden Law Partners’ overview of rollover equity (which applies to healthcare practice deals generally and to veterinary specifically), the seller is effectively betting on the sponsor’s overall portfolio performance.

In the partnership model, the dynamics are different. The seller’s retained equity is in the specific practice they continue to run.

The buyout date and formula are defined upfront. The seller receives ongoing distributions from practice-level profits during the hold period — which traditional rollover does not provide.

The seller’s return is tied to their own practice’s EBITDA growth over the hold period rather than to platform-level multiple expansion.

Work the math on a simplified example. A practice doing $1 million in current EBITDA enters a partnership deal at a 10 times multiple.

The buyer takes 70 percent ($7 million at close). The seller retains 30 percent.

The year-5 buyout formula is tied to the entry multiple applied to year-5 EBITDA. Suppose the practice grows EBITDA to $1.5 million over the 5-year period through reasonable operational improvements.

At buyout: enterprise value is 10 times $1.5 million = $15 million; the seller’s 30 percent stake is worth $4.5 million. Total economics to the seller: $7 million at close, plus 5 years of distributions on the retained 30 percent, plus $4.5 million at year 5.

The headline outcome is materially better than the $10 million headline of a straight 100 percent sale at the same entry multiple, assuming the practice actually grows.

The risk profile shifts as well. The partnership model concentrates the seller’s continued exposure on the specific practice they run — operational risk, local market risk, formula-definition risk around EBITDA add-backs and management fee allocations.

The traditional rollover model concentrates exposure on platform-level execution and macro PE conditions — fund-level performance, exit market timing, leverage, dilution from subsequent acquisitions. Different sellers reasonably prefer different exposures depending on their confidence in their own practice’s performance versus their confidence in the PE sponsor’s broader platform.

Several PE-backed veterinary consolidators are publicly using partnership or co-ownership structures. Rarebreed Veterinary Partners markets co-ownership explicitly in its company materials, emphasizing that “hospital owners can retain equity in their practice and participate in its future growth.” Mission Pet Health (formed in late 2024 through the merger of Southern Veterinary Partners and Mission Veterinary Partners, with the combined brand launched publicly in July 2025) offers structured joint venture options for larger practice groups, continuing the “Ownership Opportunities” framework established by SVP before the merger.

IVC Evidensia (the parent of VetStrategy in Canada) describes “joint-ownership” structures in many of its clinics. Encore Vet Group markets “partnership over pure acquisition” in its public materials.

Other PE-backed veterinary consolidators including NVA, AmeriVet, PetVet Care Centers, and several smaller groups use practice-level minority equity and structured put/call rights in select transactions, though their specific terms are negotiated case-by-case and not publicly enumerated.

The mechanics — the 60-70 / 30-40 split, the 5-year fixed-multiple buyout — are set out in private transaction documents (CIMs, LOIs, purchase agreements) rather than in publicly filed materials. Sell-side advisors who close deals across multiple buyers see the structural patterns recur.

Public companies and SEC filings rarely disclose the per-deal terms in detail.

If you receive a PE-backed offer in 2026, expect the buyer to propose one of these two structures — traditional rollover or partnership/JV — and possibly both as alternative options for you to choose between. Which structure is more favorable depends on your specific circumstances: your confidence in the practice’s growth trajectory over the next 5 years, your liquidity needs at close, your tax situation, and your comfort with the specific formula language defining the year-5 buyout.

None of these are abstract considerations. The difference in total deal value over 5 years between a traditional rollover and a partnership model on the same practice can easily run into seven figures depending on practice performance.

How fund economics shape the offer structure

The PE acquirer’s incentive isn’t to maximize cash at close. Their incentive is to align the seller’s economic interests with the platform’s success through closing and beyond.

That alignment manifests differently depending on where the fund is in its life cycle.

A fund early in its investment period (year 1 to 3 of the fund’s life) tends to favor cash-heavy acquisitions because the fund still has substantial committed capital to deploy. A fund mid-cycle (year 3 to 5) tends to favor mixed structures with significant rollover equity, because integration of acquired practices is the focus and the GP wants founders invested in the integration’s success.

A fund late-cycle (year 5 to 7) tends to favor structures that prepare the platform for sale, which may include earlier liquidity provisions for rollover holders.

JAB Holdings, which acquired NVA in 2019 per JAB and NVA public disclosures, operates on a longer hold horizon than typical funds. Per JAB’s public investment posture, the firm’s typical hold period exceeds 7 years, which affects how NVA approaches rollover equity terms and integration timelines compared to peers backed by more conventional PE fund structures.

None of this is documented at the individual deal level. The fund-level patterns, however, are visible in JAB’s public investment behavior.

The key implication for sellers: the PE acquirer’s “best offer” is shaped by their fund’s specific economic position at the moment of the transaction. Different buyers competing for the same practice at the same time can produce meaningfully different optimal structures depending on where each is in their fund cycle.

A seller running a competitive process where multiple PE-backed groups underwrite the same asset in parallel surfaces those differences. A seller working with one buyer in a direct negotiation sees only that buyer’s preferred structure.

Have a PE offer in hand right now? Get a Free PE Offer Review — send us the offer and we’ll decompose the cash, earnout, rollover, and non-compete terms, tell you what’s actually negotiable, and project what your practice would likely clear in a competitive process with the broader buyer pool. No upfront cost, no obligation.

How 2026 is different from 2022

Three structural shifts since the 2021-2022 cycle peak are documented in industry research.

Financing costs rose

Federal Reserve rate hikes in 2022-2024 raised the cost of PE acquisition debt. PE-backed acquirers use leverage to amplify returns.

When debt costs rise, the return math on aggressive deals stops working at peak multiples, and buyers become more selective. Octus’s 2025 sector research describes this period as one where typical add-on acquisition multiples compressed into the mid-to-high single digits.

Deal flow recovered in 2026

Capstone Partners‘ April 2026 Pet Sector M&A Update reports 18 pet sector M&A deals in the first months of 2026, more than double the 8 deals tracked in the same window of 2025. Vet & Health accounted for half of the 2026 activity.

The acceleration reflects pent-up LP pressure on fund GPs to generate liquidity events that were deferred during 2022-2024. Funds with mature vintages and committed capital are deploying again, which is increasing transaction volume.

Deal structures evolved

Per the legal commentary from Dechert and Holland & Knight cited throughout this article, the structural components of PE-backed practice acquisitions have shifted over the cycle. Cash-at-close percentages compressed slightly during the trough as buyers preserved capital.

Earnout windows lengthened in some segments. Rollover equity expectations became more standardized.

The headline multiple has recovered faster than the structure quality has in many deals.

For sellers considering a transaction in 2026, the practical implication is that the market is meaningfully more active than it was 18 months ago, but the deal structures require closer attention than they did during 2021’s peak. A 13x headline offer in 2021 with 80 percent cash at close and a 2-year earnout is structurally different from a 13x headline offer in 2026 with 65 percent cash at close and a 4-year earnout, even though the headlines look identical.

Recent named transactions in 2025-2026

Hard dollar values and structural details for individual practice acquisitions are rarely disclosed publicly. The transactions where details have leaked through credit research or public filings:

Mars Veterinary Health 2025 acquisitions

Per Mordor Intelligence’s veterinary medicine market report, Mars acquired roughly 180 U.S. veterinary clinics during 2025, expanding the global network to approximately 3,200 sites. Mars is the strategic exception in the buyer market — family-owned by Mars, Incorporated, rather than PE-backed.

Mars’s deal-by-deal structures are not publicly disclosed.

AmeriVet acquisition of Northeast Veterinary Partners (November 2025). Per Octus’s 2025 private credit research, AmeriVet Veterinary Partners announced on November 20, 2025 that it had acquired 14 new veterinary practices from Northeast Veterinary Partners.

Mission Pet Health formation (late 2024, brand launched 2025). Per the official Mission Pet Health press release dated July 21, 2025, and subsequent coverage in Bham Now (August 4, 2025), Southern Veterinary Partners and Mission Veterinary Partners completed a formal merger in late 2024 and publicly unveiled the combined brand as Mission Pet Health in mid-2025. The combined entity operates 840+ locations across 41 states with more than 20,000 employees, making it one of the largest veterinary practice operators in the United States.

Dr. Jay Price, founder and CEO of SVP, leads the combined company as CEO of Mission Pet Health.

Western Veterinary Partners continuation vehicle

Per Octus’s 2025 sector research, equity in Western Veterinary Partners moved into a continuation vehicle at a “high-teens EBITDA multiple” at the platform level. This is one of the relatively few public data points on actual platform-level multiples in 2025 veterinary M&A.

Compassion First Pet Hospitals merger into NVA (2021, ongoing integration). Per public announcements at the time, JAB Holdings‘ veterinary platform NVA absorbed Compassion First, significantly expanding NVA’s specialty hospital footprint. The deal value was not publicly disclosed.

The volume of disclosed structural detail is limited because most veterinary acquisitions occur under NDAs and don’t trigger SEC or other public disclosure requirements. The patterns sellers see across deals are mostly visible only to advisors who work on multiple transactions and who can compare structures across buyers and over time.

What competitive bidding does to PE deal structures

Through a structured sale process where multiple PE-backed groups underwrite the same practice in parallel, the differences between buyer offers extend beyond the headline multiple. Each buyer reveals their preferred structure as they bid.

The buyer most willing to pay a higher headline multiple may not also be the buyer offering the highest cash-at-close percentage, the shortest earnout, or the most favorable rollover terms.

Across the practice sales I’ve run, the gap between direct-offer outcomes and competitive-process outcomes consistently runs 3 to 7 additional multiples of EBITDA of EBITDA on the headline number — meaningful improvement on a single dimension. The total economic improvement across all components of the deal is often larger than the headline gap alone, because competitive processes also produce better cash mixes, shorter earnouts, more favorable rollover terms, and more flexible non-compete provisions.

The mechanism is the same one that operates in any competitive bidding situation. Buyers offer their lowest defensible structure when they think they have no competition.

They offer their best defensible structure when they know they’re competing against alternatives. Each buyer has internal pricing committee approval ranges for both.

A structured process surfaces the upper end of those ranges across all buyers in parallel.

For a deeper walk-through of the practice sale process itself, see our complete guide to selling a veterinary practice.

The regulatory layer affecting PE deal structures

Per legal commentary from Dechert LLP and Holland & Knight in 2025-2026, several states have introduced legislation that directly affects private equity-backed healthcare and veterinary practice acquisitions. New York’s Assembly Bill 9042 and North Carolina’s Senate Bill 570 are among the most cited examples.

The legislation generally targets:

• Corporate-practice-of-medicine rules that restrict who can own or control medical and veterinary practices
• Management services organization structures that PE-backed groups use to own shared services across multiple practices
• Non-compete provisions in employment agreements with selling doctors
• Ownership thresholds at the clinical entity level for licensed practitioners

The economic effect on deal pricing in regulated states is generally modest. The structural effect on deals is more significant.

Rollover equity terms are being adjusted to put more economic ownership at the clinical entity level. Non-competes are being either shortened in geography and duration or traded for higher cash at close.

MSO structures are being redesigned to satisfy new ownership thresholds.

For sellers contemplating a sale in 2026 in states with active legislation, the regulatory layer adds complexity to closing but doesn’t materially change what the practice is worth. It does affect what’s negotiable within the deal — particularly around earnout protections, post-sale ownership terms, and the geographic scope of any non-compete provision.

“I had previously looked at selling the practice on my own, and I had talked to five different companies about this and had gone through the process individually, and none of it turned out to my satisfaction. After I signed up with Tom, he marketed me to these interested companies. There was competition amongst those interested. It was so relieving at the end of it to know that I got the very best deal possible!”

— David Graeff, Cedar Rapids, Iowa

What to do if you have a PE offer in hand

A PE-backed acquisition team has reached out. They’ve teased a multiple on the first call.

They’ve asked for 30 days exclusive to “complete diligence and finalize terms.” The temptation to engage on their terms is real, particularly because the proposed number sounds attractive in isolation.

Three concrete steps before signing anything:

The first is documenting a defensible normalized EBITDA number. Buyers price your practice against the normalized figure, not the raw P&L number.

Building that normalization properly typically takes 30 to 60 days with the right advisor and is the foundation of every downstream negotiation. Our veterinary practice EBITDA multiples guide covers the normalization process in depth.

The second is evaluating the offer on all four economic components, not just the headline multiple. The cash at close, the earnout structure (length, metric, protective provisions), the rollover equity terms (percentage, lockup, governance rights), and the non-compete scope.

Each is a separate negotiation. Treating them as a single take-it-or-leave-it package is where most seller leverage gets lost.

The third is not signing exclusivity with the first buyer before evaluating the broader buyer pool. The exclusivity request is industry standard.

So is the cost of granting it. A structured competitive process with multiple qualified bidders — what we call the Elite Selling System — consistently produces better outcomes on the headline multiple and on the deal structure than a direct negotiation with one buyer.

The “velvet rope” is the qualification gate: we hand-select and vet only the buyers who fit your practice, then run a private bidding window inside that group. That filter is what creates the leverage that moves the number.

Get a Free PE Offer Review →

Send us the offer you have. We’ll decompose it the way I’d walk through it with a vet over dinner — cash, earnout, rollover, non-compete, post-sale employment, regulatory considerations — and tell you what your practice would likely clear in a structured competitive process with the broader buyer pool that fits your specific profile.

The review is free and there’s no obligation to engage further. Transitions Elite operates on a success-based engagement model — no upfront fees, no retainer.

We only get paid when a deal closes, and only out of the value our process delivers above what you would have realized on your own.

---

Frequently asked questions

What is the partnership or joint venture model in veterinary PE deals?

An increasingly common 2025-2026 deal structure where the PE-backed buyer acquires a majority stake in the practice itself (typically 60 to 80 percent) rather than 100 percent, and the seller retains the remaining 20 to 40 percent as direct equity in the practice. The contract includes a put/call mechanism with a defined buyout date (often year 5) and a formula buyout price often tied to the entry multiple applied to then-current EBITDA.

Differs from traditional rollover equity, which is held at the platform level rather than the practice level. Used publicly by Rarebreed Veterinary Partners, Southern Veterinary Partners, IVC Evidensia, Encore Vet Group, and others per their company materials and industry M&A commentary.

How does the partnership model differ from traditional rollover equity?

Traditional rollover equity is a minority stake in the platform or MSO holding company, illiquid until the PE sponsor exits the platform (typically 4 to 7 years, uncertain timing), with the buyout value determined by the eventual platform exit multiple. The partnership model is a minority stake in the practice entity itself, with a defined buyout date and a formula-based buyout price often tied to the entry deal multiple, plus ongoing distributions on the retained equity during the hold period.

How does private equity make money buying veterinary practices?

Private equity firms acquire individual veterinary practices, integrate them into a larger platform, and eventually sell the combined platform at a higher multiple than the per-practice acquisition multiple. The strategy is called multiple arbitrage.

Per Octus’s 2025 sector research, recent veterinary platform recapitalizations have traded at high-teens EBITDA multiples at the platform level, while individual practice acquisitions trade at the single-digit to low-teens range described in Capstone Partners‘ April 2026 market commentary.

Why does the headline multiple in a PE veterinary offer not equal the cash that lands at closing?

PE-backed offers typically include four components: cash at closing, earnouts, rollover equity, and occasionally seller notes. Per healthcare M&A legal commentary from Dechert and Holland & Knight in 2025-2026, the typical structure allocates cash at close in the 60 to 80 percent range of total deal value, with the rest split among contingent payments.

What is rollover equity and should I accept it?

Rollover equity is the portion of ownership a seller retains in the post-sale entity instead of taking all cash at close. The equity is illiquid until the platform owner exits, which typically occurs 3 to 7 years post-close.

Whether to accept rollover depends on the seller’s risk tolerance, liquidity needs, and views on the platform’s eventual exit timeline.

How do earnouts work in PE veterinary practice acquisitions?

An earnout is part of the sale price paid after closing, contingent on the practice hitting agreed performance targets. In healthcare practice acquisitions, per legal commentary from Dechert and Holland & Knight in 2025-2026, earnouts typically run 1 to 3 years with performance metrics tied to revenue, gross profit, or EBITDA.

Realization rates vary widely depending on the earnout structure.

Why is 2026 a different PE veterinary market than 2021-2022?

Financing costs increased after Federal Reserve rate hikes in 2022-2024, compressing return math on aggressive deals. Multiples repriced from peak.

Capstone Partners describes 2024 as the trough year. The 2026 environment shows clear recovery in deal volume — Capstone reports 18 pet sector deals in the first months of 2026, more than double the same window of 2025.

How are state regulations affecting PE veterinary deal structures?

Per Dechert LLP and Holland & Knight commentary in 2025-2026, several states have introduced legislation directly affecting private equity-backed healthcare practice acquisitions. New York’s AB 9042, North Carolina’s SB 570, and similar bills affect deal structuring (rollover equity terms, non-compete enforceability, ownership thresholds) rather than directly capping purchase prices.

What is multiple arbitrage in private equity veterinary deals?

Multiple arbitrage is the core economic engine of private equity veterinary roll-ups. The strategy: buy individual practices at lower multiples, integrate them operationally into a larger platform, then sell the combined entity at a higher multiple.

The spread between per-practice acquisition multiples and platform-level exit multiples, multiplied across many practices, generates the bulk of PE veterinary investment returns.

---

Sources

Industry M&A research and market data

1. Capstone Partners. “Pet Sector M&A Update — April 2026.” capstonepartners.com
2. Octus. “Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion — VSOs Under Increasing Pressure.” 2025. octus.com
3. Mordor Intelligence. “Veterinary Medicine Market.” mordorintelligence.com

Veterinary profession data

4. AVMA. “Just released: AVMA data and insights on the veterinary profession.” avma.org

Legal, regulatory, and deal structure analysis

5. Dechert LLP. “Healthcare Investments Flash Alert — Latest Developments.” 2025. dechert.com
6. Holland & Knight. “Q1 Recap on Proposed Legislation Affecting Healthcare Consolidation.” 2026. hklaw.com
7. MB Law Firm. “Joint Ventures, Longer Commitments, and the Rise of Earn-Outs.” 2025. mblawfirm.com
8. Linden Law Partners. “Rollover Equity in M&A: Structure, Terms & Key Considerations.” lindenlawpartners.com
9. CLA (CliftonLarsonAllen). “Rollover Equity and Valuation Techniques.” claconnect.com

Buyer company disclosures and merger announcements

10. Mission Pet Health. “Southern Veterinary Partners and Mission Veterinary Partners Join Together as Mission Pet Health.” July 21, 2025. missionpethealth.com
11. Bham Now. “Birmingham’s Southern Veterinary Partners merges to form new national giant.” August 4, 2025.
12. Rarebreed Veterinary Partners — corporate “Co-Ownership” materials.
13. Encore Vet Group — corporate “Partnership” materials.
14. IVC Evidensia — company disclosures on joint-ownership clinic structures.
15. National Veterinary Associates — company disclosures, 2025.
16. JAB Holdings — public commentary on 2019 NVA acquisition.
17. Mars, Incorporated — company disclosures and brand materials.